JMJoEllyn McMillan

JoEllyn McMillan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


JoEllyn McMillan has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Per- and polyfluoroalkyl substances (PFAS) mixtures in rural Nebraska drinking water: Characterization and human health risk screening

    by Sarah Tucker, Daniel D. Snow, Rachael Birn, Elizabeth Cole, Alex Egbuchiem, He Bai, JoEllyn McMillan, Kristina W. Kintziger, Aaron Yoder

  • Open Access

    Exonic Disruption Facilitates Antiviral CRISPR-Cas9 Activity for Multistrain HIV-1 Elimination

    by Jonathan Herskovitz, Mahmudul Hasan, Milankumar Patel, Wilson R. Blomberg, Jacob D. Cohen, Jatin Machhi, Daniel Stein, Evan A. Schroder, JoEllyn McMillan, Channabasavaiah B. Gurumurthy, et al.

    A barrier to HIV-1 cure rests in the persistence of proviral DNA in infected CD4+ leukocytes. The high mutation rate of HIV-1 gives rise to numerous circulating strains with increased capacity for immune evasion and antiretroviral drug resistance. To facilitate viral elimination while accounting for this diversity, we propose genetic inactivation of proviral DNA with CRISPR-spCas9. We designed a library of “mosaic gRNAs” against a HIV-1 consensus sequence constructed from 4004 clinical strains, targeting the viral transcriptional regulator tat. Testing in 7 HIV-1 transmitted founder strains led, on average, to viral reductions of 82% with tandem TatD and TatE (TatDE) treatment. No off-target cleavages were recorded. Lentiviral transduction of TatDE attenuated latency reversal by 94% in HIV-infected, transcriptionally silent ACH2 T cells. In all, TatDE guide RNAs successfully disrupted 5 separate HIV-1 exons ( tat 1-2 / rev 1-2 / gp41 ) providing a pathway for CRISPR-directed HIV-1 cure therapies. Significance Statement: Over 38 million individuals worldwide are infected with HIV-1, which necessitates lifelong dependence on antiretroviral therapy (ART) to prevent viral replication that leads to AIDS. Efforts to rid hosts of HIV-1 are limited by the virus’ abilities to integrate proviral DNA in nuclei, mutate their genomes, and lay dormant for decades during ART treatment. We developed mosaic guide RNAs, TatD and TatE, for CRISPR-Cas9 that recognize the majority of known HIV-1 strains and inactivate 94% of proviral DNA in latently infected cells. Tandem TatDE-CRISPR inactivation of 5 viral exons (t at 1-2 , rev 1-2 , and gp41 ), which blocked HIV-1 replication for 28 days in CD4+ T cells without unwanted editing to the host genome, may serve as a viable strategy for HIV cure.


  • Open Access

    EcoHIV infection of mice establishes latent viral reservoirs in T cells and active viral reservoirs in macrophages that are sufficient for induction of neurocognitive impairment

    by Chao-Jiang Gu, Alejandra Borjabad, Eran Hadas, Jennifer Kelschenbach, Boe-Hyun Kim, Wei Chao, Ottavio Arancio, Jin Suh, Bruce Polsky, JoEllyn McMillan, et al.

    Suppression of HIV replication by antiretroviral therapy (ART) or host immunity can prevent AIDS but not other HIV-associated conditions including neurocognitive impairment (HIV-NCI). Pathogenesis in HIV-suppressed individuals has been attributed to reservoirs of latent-inducible virus in resting CD4+ T cells. Macrophages are persistently infected with HIV but their role as HIV reservoirs in vivo has not been fully explored. Here we show that infection of conventional mice with chimeric HIV, EcoHIV, reproduces physiological conditions for development of disease in people on ART including immunocompetence, stable suppression of HIV replication, persistence of integrated, replication-competent HIV in T cells and macrophages, and manifestation of learning and memory deficits in behavioral tests, termed here murine HIV-NCI. EcoHIV established latent reservoirs in CD4+ T lymphocytes in chronically-infected mice but could be induced by epigenetic modulators ex vivo and in mice. In contrast, macrophages expressed EcoHIV constitutively in mice for up to 16 months; murine leukemia virus (MLV), the donor of gp80 envelope in EcoHIV, did not infect macrophages. Both EcoHIV and MLV were found in brain tissue of infected mice but only EcoHIV induced NCI. Murine HIV-NCI was prevented by antiretroviral prophylaxis but once established neither persistent EcoHIV infection in mice nor NCI could be reversed by long-acting antiretroviral therapy. EcoHIV-infected, athymic mice were more permissive to virus replication in macrophages than were wild-type mice, suffered cognitive dysfunction, as well as increased numbers of monocytes and macrophages infiltrating the brain. Our results suggest an important role of HIV expressing macrophages in HIV neuropathogenesis in hosts with suppressed HIV replication. Antiretroviral therapy (ART) transformed HIV infection from a death sentence to a chronic, largely manageable condition, with near preservation of immune systems and extended life expectancies in infected people. Despite effective ART, roughly half of HIV-infected people suffer problems in learning and memory that can impair day to day activities. In addition, HIV persists in largely silent states during ART, but it can be reactivated and produce infectious, possibly pathogenic virus. We addressed these two issues by infecting mice with a genetically engineered HIV that infects rodents instead of human beings. Unlike infected people we find that infected mice maintain good immune responses to HIV that appear to act like ART to keep virus levels low and allow mice to resist other complications. Like infected people, HIV-infected mice are subject to learning and memory problems; they carry silenced HIV long-term in T lymphocytes but we found that macrophages, infected in both humans and mice, continue to produce HIV in mice indicating that additional means may be needed to control HIV-infected macrophages. Moreover, in mice lacking T lymphocytes HIV infection of macrophages is sufficient to drive dysfunction in learning and memory. Like in people living with HIV, antiretroviral therapy in chronically-infected mice is ineffective against existing HIV infection and cognitive disease. Controlling this infection and brain disease may require tools tailored to actively expressed virus.


  • Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC–MS/MS

    by Nagsen Gautam, Zhiyi Lin, Mary G Banoub, Nathan A Smith, Audai Maayah, JoEllyn McMillan, Howard E. Gendelman, Yazen Alnouti


  • Open Access

    Optimizing the Preparation and Stability of Decorated Antiretroviral Drug Nanocrystals

    by Tian Zhou, Zhiyi Lin, Pavan Puligujja, Diana Palandri, James Hilaire, Mariluz Araínga, Nathan Smith, Nagsen Gautam, JoEllyn McMillan, Yazen Alnouti, et al.

    Aim: While the therapeutic potential for current long-acting (LA) antiretroviral therapy (ART) is undeniable, ligand-decorated nanoformulated LA-ART could optimize drug delivery to viral reservoirs. The development of decorated ART hinges, however, on formulation processes and manufacture efficiencies. To this end, we compared manufacture and purification techniques for ligand-decorated antiretroviral drug nanocrystals. Materials & methods: Ligand-decorated nanoparticle manufacturing was tested using folic acid (FA) nanoformulated cabotegravir. Results: Direct manufacturing of FA-cabotegravir resulted in stable particles with high drug loading and monocyte–macrophage targeting. A one step ‘direct’ scheme proved superior over differential centrifugation or tangential flow filtration facilitating particle stability and preparation simplicity and efficiency. Conclusion: Direct manufacturing of FA nanoparticles provides a path toward large-scale clinical grade manufacturing of cell-targeted LA-ART. Lay abstract Folic acid (FA) decoration on the surface of nanocrystals can be achieved by mixing FA conjugated poloxamer 407 (FA-P407) and native P407 in varied ratios followed by size reduction by homogenization and differential centrifugation or tangential flow filtration to remove excess unbound polymers. The optimized manufacturing scheme is by direct homogenization with predetermined quantity of FA conjugated P407. Direct manufacturing method yields stable homogenous nanoparticles with high drug loading.


  • Nanoformulated Medicines

    by Upal Roy, Shantanu Balkundi, JoEllyn McMillan, Howard E. Gendelman

    Nanomaterials are being exploited with the goals to improve antiretroviral therapeutic efficacy, pharmacokinetics, and patient compliance. Importantly such materials can also be used for bioimaging to improve disease diagnosis and therapeutic monitoring. The targeted objectives all together are to attenuate human immunodeficiency virus (HIV) infection and positively affect the outcomes of disease manifestations in the infected human host. We posit that antiretroviral therapy delivery can be enhanced by formulating or encapsulating drugs with surfactants. Such nanoformulated drugs are readily taken up by the reticuloendothelial system (RES), the natural target for HIV. Recent works have explored the development of cell-based delivery systems using macrophages as drug carriers. This scheme has been shown to enhance nervous system RES delivery as macrophages are actively phagocytic cells and readily cross tissue barriers. Another major advantage of using cells as drug carriers is the potential to deliver a broad range of medicines with different biochemical properties to disease sites. This chapter discusses the potentials and perils for nanoformulated drug developments, with a particular focus on antiretroviral agents.